Surgeries & Interventions

The First Dissolvable Heart Monitor and Pacer

A team of Northwestern and George Washington scientists took a big step towards revolutionizing how patients are monitored and treated after major cardiac events, unveiling the first dissolvable cardiac mapping and pacing device.

The flexible, transparent, postage stamp-sized device attaches to the surface of the heart and uses sensors and actuators to assess cardiac activity, stream info to monitoring clinicians, and deliver treatments, before dissolving into the body “similar to absorbable stitches” after six weeks. 

That might sound like a dissolvable pacemaker, which would still be impressive, but initial testing shows that it’s capable of far more than current pacemakers. The device…

  • Can be placed on more areas of the heart’s surface
  • Spatiotemporally maps a range of electrical activity (EG and optically), showing which exact areas of the heart are (or aren’t) functioning.
  • Delivers electrical stimuli to targeted areas to quickly stop atrial fibrillation or AV blocks, and maps how this pacing affects different parts of the heart.
  • Uses a transparent design to ensure that the device won’t interfere with optical diagnostics/therapies and other image-guided procedures.

Plus, its bioresorbable design means that it doesn’t have to be extracted after the monitoring period, reducing costs and complications associated with removal procedures.

Noting that one-third of heart disease deaths in the U.S. result from complications that occur during the initial months after a major cardiac event, the researchers have big ambitions for their unique new device. 

  • As you might expect, they believe it could significantly improve short-term monitoring and treatments for patients recovering from MACE and cardiac surgeries, without requiring removal surgeries after their recovery is complete. 
  • They also see the technologies and methods they used supporting other breakthroughs, including the development of new therapies, guiding surgical procedures, and for other forms of postoperative monitoring.

The Takeaway
Although a lot more R&D and RCTs will be needed before clinical use is even a possibility, this device’s potential to address some of the biggest challenges with post-MACE care and current pacemaker technology seems to be worth waiting for. And given the related advances we’re seeing in pacemaker materials and dissolvability, we could be seeing a wave of similar innovations in the coming years.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Atrial Fibrillation November 10, 2025

ARREST-AF and the Importance of Lifestyle Post-Ablation November 10, 2025

Catheter ablation for atrial fibrillation might be missing half its potential, after results from the ARREST-AF trial demonstrated that structured lifestyle and risk factor management significantly increases a patient’s 12-month freedom from arrhythmia while cutting recurrence risk nearly in half. That could be changing now, thanks to the ARREST-AF trial which randomized 122 patients with […]

Heart Failure November 6, 2025

PREVENT-TAHA8 Supports Stem Cells for Post-MI HF November 6, 2025

Stem cell therapy for post-MI heart failure might deserve a second look, after the PREVENT-TAHA8 trial demonstrated that mesenchymal stem cell infusion within days of STEMI significantly reduced 3-year HF incidence. Based in Iran, the PREVENT-TAHA8 trial, randomized 396 patients following LAD STEMI with LVEF <40%, to receive either an intracoronary mesenchymal stem cell infusion […]

Structural Heart November 3, 2025

Abbott’s Tendyne TMVR System Works Even in the Sickest MR Patients November 3, 2025

New research presented at TCT 2025 suggests that Abbott’s FDA-approved Tendyne TMVR system leads to significantly better health outcomes in patients with severe mitral annular calcification who were previously considered untreatable. The SUMMIT-MAC trial enrolled 103 patients with severe MAC and found that the challenging patient population showed strong outcomes despite extreme pathology… However, patients […]